Merifin Capital logo

Merifin Capital

Europe, Brussels Hoofdstedelijk Gewest, Belgium, Brussels

Description

Merifin Capital is a European private investment company focused on traditional and alternative asset classes.

Investor Profile

Merifin Capital has made 12 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series A (25%)
  • Series Unknown (17%)
  • Series D (17%)
  • Series C (17%)
  • Private Equity (8%)
  • Series E (8%)
  • Series B (8%)

Country Focus

  • United Kingdom (33%)
  • United States (25%)
  • Germany (17%)
  • Italy (17%)
  • France (8%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Genetics
  • Therapeutics
  • Manufacturing
  • E-commerce
  • Semiconductor
  • Electronics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Merifin Capital frequently co-invest with?

360 Capital
Europe, Ile-de-France, France, Paris
Co-Investments: 2
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 2
Co-Investments: 2
Advent Life Sciences
Europe, England, United Kingdom, London
Co-Investments: 1
Novo Holdings
Europe, Hovedstaden, Denmark, Hellerup
Co-Investments: 1
Astellas Venture Management
North America, California, United States, Menlo Park
Co-Investments: 2
Brace Pharma
North America, Maryland, United States, Rockville
Co-Investments: 1
QF
Europe, Vlaams-Brabant, Belgium, Leuven
Co-Investments: 2
Aisling Capital
North America, New York, United States, New York
Co-Investments: 1
Sunstone Life Science Ventures
Europe, Hovedstaden, Denmark, Copenhagen
Co-Investments: 2

What are some of recent deals done by Merifin Capital?

F2G

Manchester, Manchester, United Kingdom

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

BiotechnologyGeneticsHealth CareMedicalPharmaceutical
Private EquityJun 20, 2016
Amount Raised: $60,000,000
DoveConviene

Sestu, Sardegna, Italy

DoveConviene designs and develops a digital platform which helps people to shop by saving money through offers and leaflets.

E-CommercePrintingShopping
Series CSep 25, 2015
Amount Raised: $11,196,052
DoveConviene

Sestu, Sardegna, Italy

DoveConviene designs and develops a digital platform which helps people to shop by saving money through offers and leaflets.

E-CommercePrintingShopping
Series BDec 3, 2014
Amount Raised: $6,416,481
Flayr

Paris, Ile-de-France, France

Flayr enables users to discover and purchase outsourced and crowdsourced branded apparel, shoes and accessories.

ApparelE-CommerceEdiscovery
Series ANov 20, 2013
Amount Raised: $6,100,000
F2G

Manchester, Manchester, United Kingdom

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

BiotechnologyGeneticsHealth CareMedicalPharmaceutical
Series UnknownSep 5, 2012
Amount Raised: $30,000,000
F2G

Manchester, Manchester, United Kingdom

F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.

BiotechnologyGeneticsHealth CareMedicalPharmaceutical
Series UnknownAug 18, 2008
Amount Raised: $11,753,687
Plastic Logic Germany

Dresden, Sachsen, Germany

Plastic Logic Germany leads the way in developing, manufacturing and commercializing flexible electrophoretic displays (EPD).

ElectronicsManufacturingProduct Design
Series DJan 6, 2007
Amount Raised: $100,000,000
Metara

Sunnyvale, California, United States

Metara manufactures chemical metrology tools for the semiconductor industry to be used in the chemical monitoring and controlling processes.

ChemicalElectronicsManufacturingSemiconductorTelecommunications
Series ENov 15, 2005
Amount Raised: $11,500,000
DanioLabs

Cambridge, Cambridgeshire, United Kingdom

DanioLabs is a private UK drug discovery company.

BiotechnologyTherapeutics
Series AJan 17, 2005
Amount Raised: $5,959,920
immatics biotechnologies

Tübingen, Baden-Wurttemberg, Germany

Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.

BiotechnologyMedicalTherapeutics
Series AFeb 11, 2004
Amount Raised: $9,911,969